These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 24176644)

  • 1. Treatment adherence and persistence in adult ADHD: results from a twenty-four week controlled clinical trial with extended release methylphenidate.
    Sobanski E; Retz W; Fischer R; Ose C; Alm B; Hennig O; Rösler M
    Eur Psychiatry; 2014 Jun; 29(5):324-30. PubMed ID: 24176644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors and impact of non-adherence in adults with attention-deficit/hyperactivity disorder receiving OROS methylphenidate: results from a randomized, placebo-controlled trial.
    Kooij JJ; Rösler M; Philipsen A; Wächter S; Dejonckheere J; van der Kolk A; van Agthoven M; Schäuble B
    BMC Psychiatry; 2013 Jan; 13():36. PubMed ID: 23347693
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.
    Newcorn JH; Nagy P; Childress AC; Frick G; Yan B; Pliszka S
    CNS Drugs; 2017 Nov; 31(11):999-1014. PubMed ID: 28980198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of HLD200, Delayed-Release and Extended-Release Methylphenidate, in Children with Attention-Deficit/Hyperactivity Disorder.
    Pliszka SR; Wilens TE; Bostrom S; Arnold VK; Marraffino A; Cutler AJ; López FA; DeSousa NJ; Sallee FR; Incledon B; Newcorn JH
    J Child Adolesc Psychopharmacol; 2017 Aug; 27(6):474-482. PubMed ID: 29172680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Delayed-Release and Extended-Release Methylphenidate on Caregiver Strain and Validation of Psychometric Properties of the Caregiver Strain Questionnaire: Results from a Phase 3 Trial in Children with Attention-Deficit/Hyperactivity Disorder.
    López FA; Faraone SV; Newcorn JH; Doll HA; Rhoten S; Lewis HB; Khan TF; DeSousa NJ; Sallee FR; Incledon B
    J Child Adolesc Psychopharmacol; 2021 Apr; 31(3):179-186. PubMed ID: 33797983
    [No Abstract]   [Full Text] [Related]  

  • 6. A randomised, placebo-controlled, 24-week, study of low-dose extended-release methylphenidate in adults with attention-deficit/hyperactivity disorder.
    Rösler M; Fischer R; Ammer R; Ose C; Retz W
    Eur Arch Psychiatry Clin Neurosci; 2009 Mar; 259(2):120-9. PubMed ID: 19165529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Post Hoc Comparison of Prior ADHD Medication Dose and Optimized Delayed-release and Extended-release Methylphenidate Dose in a Pivotal Phase III Trial.
    Childress AC; Uchida CL; Po MD; DeSousa NJ; Incledon B
    Clin Ther; 2020 Dec; 42(12):2332-2340. PubMed ID: 33168234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Osmotic Release Oral System Methylphenidate Versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder in Chinese Youth: 8-Week Comparative Efficacy and 1-Year Follow-Up.
    Su Y; Yang L; Stein MA; Cao Q; Wang Y
    J Child Adolesc Psychopharmacol; 2016 May; 26(4):362-71. PubMed ID: 26779845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiscale assessment of treatment efficacy in adults with ADHD: a randomized placebo-controlled, multi-centre study with extended-release methylphenidate.
    Retz W; Rösler M; Ose C; Scherag A; Alm B; Philipsen A; Fischer R; Ammer R;
    World J Biol Psychiatry; 2012 Jan; 13(1):48-59. PubMed ID: 21155632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Twenty-four-week treatment with extended release methylphenidate improves emotional symptoms in adult ADHD.
    Rösler M; Retz W; Fischer R; Ose C; Alm B; Deckert J; Philipsen A; Herpertz S; Ammer R
    World J Biol Psychiatry; 2010 Aug; 11(5):709-18. PubMed ID: 20353312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Continuity in methylphenidate treatment of adults with attention-deficit/hyperactivity disorder.
    Olfson M; Marcus SC; Zhang HF; Wan GJ
    J Manag Care Pharm; 2007 Sep; 13(7):570-7. PubMed ID: 17874863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of a novel biphasic controlled-release methylphenidate formula in adults with attention-deficit/hyperactivity disorder: results of a double-blind, placebo-controlled crossover study.
    Jain U; Hechtman L; Weiss M; Ahmed TS; Reiz JL; Donnelly GA; Harsanyi Z; Darke AC
    J Clin Psychiatry; 2007 Feb; 68(2):268-77. PubMed ID: 17335326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of Methylphenidate Hydrochloride Extended-Release Capsules (Aptensio XR™) in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Phase III, Randomized, Double-Blind Study.
    Wigal SB; Nordbrock E; Adjei AL; Childress A; Kupper RJ; Greenhill L
    CNS Drugs; 2015 Apr; 29(4):331-40. PubMed ID: 25877989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. OROS-methylphenidate efficacy on specific executive functioning deficits in adults with ADHD: a randomized, placebo-controlled cross-over study.
    Bron TI; Bijlenga D; Boonstra AM; Breuk M; Pardoen WF; Beekman AT; Kooij JJ
    Eur Neuropsychopharmacol; 2014 Apr; 24(4):519-28. PubMed ID: 24508533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A prospective open-label trial of long-acting liquid methylphenidate for the treatment of attention deficit/hyperactivity disorder in intellectually capable adults with autism spectrum disorder.
    Joshi G; DiSalvo M; Wozniak J; Ceranoglu TA; Yule A; Surman C; Fried R; Galdo M; Hoskova B; Belser A; Biederman J
    World J Biol Psychiatry; 2020 Apr; 21(4):274-290. PubMed ID: 31607204
    [No Abstract]   [Full Text] [Related]  

  • 16. Open-label dose optimization of methylphenidate modified release long acting (MPH-LA): a post hoc analysis of real-life titration from a 40-week randomized trial.
    Huss M; Ginsberg Y; Arngrim T; Philipsen A; Carter K; Chen CW; Gandhi P; Kumar V
    Clin Drug Investig; 2014 Sep; 34(9):639-49. PubMed ID: 25015027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study.
    Adler LA; Zimmerman B; Starr HL; Silber S; Palumbo J; Orman C; Spencer T
    J Clin Psychopharmacol; 2009 Jun; 29(3):239-47. PubMed ID: 19440077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Once-daily multilayer-release methylphenidate in a double-blind, crossover comparison to immediate-release methylphenidate in children with attention-deficit/hyperactivity disorder.
    Weiss M; Hechtman L; Turgay A; Jain U; Quinn D; Ahmed TS; Yates T; Reiz JL; Donnelly GA; Harsanyi Z; Darke AC
    J Child Adolesc Psychopharmacol; 2007 Oct; 17(5):675-88. PubMed ID: 17979587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Less discontinuation of ADHD drug use since the availability of long-acting ADHD medication in children, adolescents and adults under the age of 45 years in the Netherlands.
    van den Ban E; Souverein PC; Swaab H; van Engeland H; Egberts TC; Heerdink ER
    Atten Defic Hyperact Disord; 2010 Dec; 2(4):213-20. PubMed ID: 21258431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of transitioning from extended-release methylphenidate onto osmotic, controlled-release methylphenidate in children/adolescents with ADHD: results of a 3-month non-interventional study.
    Wolff C; Alfred A; Lindermüller A; Rettig K; Mattejat F; Gerwe M; Slawik L; Schäuble B
    Curr Med Res Opin; 2011; 27 Suppl 2():35-44. PubMed ID: 21787126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.